{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T10:59:38Z","timestamp":1792839578039,"version":"4.5.0"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":4170,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2004,4]]},"abstract":"<jats:sec>\n            <jats:title\/>\n            <jats:p>Primary biliary cirrhosis frequently progresses despite treatment with ursodeoxycholic acid (UDCA), the only approved therapy. Previous studies suggested that colchicine and methotrexate may improve biochemical tests of liver function, symptoms, and liver histology. The aim of the present study was to determine if the addition of colchicine or methotrexate to UDCA would improve survival free of liver transplantation. Eighty-five patients with histologically confirmed primary biliary cirrhosis whose serum alkaline phosphatase levels were at least twice the normal level and who were not yet candidates for liver transplantation were randomly assigned to receive colchicine or methotrexate in a double-blind study. UDCA was administered to all patients after 2 years. The primary end point was survival free of liver transplantation. Patients were followed up for a total of up to 10 years or until treatment failure. Data were analyzed on an intention-to-treat basis. Transplant-free survival was similar in both groups: 0.57 for colchicine plus UDCA and 0.44 for methotrexate plus UDCA, results that are similar to those predicted by the Mayo prognostic model. Significant improvement in liver biochemical tests and liver histology was observed in a subset of patients in both treatment groups who remained in the study for all 10 years. In conclusion, neither colchcine plus UDCA nor methotrexate plus UDCA improved survival beyond that predicted by the Mayo prognostic model. However, clinical, histologic, and biochemical improvement observed among those who remained in the study for 10 years suggests a possible benefit of these drugs in a subset of patients. (Hepatology 2004;39:915-923.)<\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/hep.20103","type":"journal-article","created":{"date-parts":[[2004,3,26]],"date-time":"2004-03-26T08:01:42Z","timestamp":1080288102000},"page":"915-923","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":69,"title":["A randomized controlled trial of colchicine plus ursodiol versus methotrexate plus ursodiol in primary biliary cirrhosis: Ten-year results"],"prefix":"10.1097","volume":"39","author":[{"given":"Marshall M.","family":"Kaplan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori Lyn","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A. L.","family":"Bonis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-9-20241201","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1056\/NEJM199611213352107","article-title":"Primary biliary cirrhosis.","volume":"335","author":"Kaplan","year":"1996","journal-title":"N Engl J Med"},{"key":"R2-9-20241201","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/hep.1840190314","article-title":"Predictive factors in ursodeoxycholic acid-treated patients with primary biliary cirrhosis: role of serum markers of connective tissue.","volume":"19","author":"Poupon","year":"1994","journal-title":"HEPATOLOGY"},{"key":"R3-9-20241201","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/hep.1840190512","article-title":"The Canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis.","volume":"19","author":"Heathcote","year":"1994","journal-title":"HEPATOLOGY"},{"key":"R4-9-20241201","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/0016-5085(94)90021-3","article-title":"Ursodeoxycholic acid in the treatment of primary biliary cirrhosis.","volume":"106","author":"Lindor","year":"1994","journal-title":"Gastroenterology"},{"key":"R5-9-20241201","first-page":"759","article-title":"A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis.","volume":"22","author":"Combes","year":"1995","journal-title":"HEPATOLOGY"},{"key":"R6-9-20241201","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S0140-6736(98)11293-X","article-title":"Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis.","volume":"354","author":"Goulis","year":"1999","journal-title":"Lancet"},{"key":"R7-9-20241201","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S0168-8278(01)00061-7","article-title":"Ursodeoxycholic acid for primary biliary cirrhosis: lesson for the future?","volume":"34","author":"Gluud","year":"2001","journal-title":"J Hepatol"},{"key":"R8-9-20241201","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJM198612043152304","article-title":"A prospective trial of colchicine for primary biliary cirrhosis.","volume":"315","author":"Kaplan","year":"1986","journal-title":"N Engl J Med"},{"key":"R9-9-20241201","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/0016-5085(91)90085-Y","article-title":"Treatment of primary biliary cirrhosis with low-dose weekly methotrexate.","volume":"101","author":"Kaplan","year":"1991","journal-title":"Gastroenterology"},{"key":"R10-9-20241201","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1046\/j.1365-2036.2001.01018.x","article-title":"Ten-year combination treatment with colchicine and ursodeoxycholic acid for primary biliary cirhhosis: a double-blind, placebo-controlled trial on symptomatic patients.","volume":"9","author":"Battezzati","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"R11-9-20241201","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1002\/hep.510240520","article-title":"A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis. UDCA-PBC Study Group.","volume":"24","author":"Poupon","year":"1996","journal-title":"HEPATOLOGY"},{"key":"R12-9-20241201","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1053\/gast.1999.0029900400","article-title":"Low-dose methotrexate is ineffective in primary biliary cirrhosis: long-term results of a placebo-controlled trial.","volume":"117","author":"Hendrickse","year":"1999","journal-title":"Gastroenterology"},{"key":"R13-9-20241201","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1572-0241.2003.07173.x","article-title":"Methotrexate therapy for primary biliary cirrhosis.","volume":"98","author":"Bach","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"R14-9-20241201","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1056\/NEJM199105303242204","article-title":"A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group.","volume":"324","author":"Poupon","year":"1991","journal-title":"N Engl J Med"},{"key":"R15-9-20241201","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0016-5085(99)70403-8","article-title":"A prospective trial of colchicine and methotrexate in the treatment of primary biliary cirrhosis.","volume":"117","author":"Kaplan","year":"1999","journal-title":"Gastroenterology"},{"key":"R16-9-20241201","doi-asserted-by":"crossref","first-page":"429","DOI":"10.7326\/0003-4819-109-5-429","article-title":"Primary biliary cirrhosis treated with low-dose oral pulse methotrexate.","volume":"109","author":"Kaplan","year":"1988","journal-title":"Ann Intern Med"},{"key":"R17-9-20241201","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1053\/gast.1996.v110.pm8613058","article-title":"Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis.","volume":"110","author":"Lindor","year":"1996","journal-title":"Gastroenterology"},{"key":"R18-9-20241201","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/hep.1840100102","article-title":"Prognosis in primary biliary cirrhosis: model for decision making.","volume":"10","author":"Dickson","year":"1989","journal-title":"HEPATOLOGY"},{"key":"R20-9-20241201","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1478-3231.1999.tb00020.x","article-title":"Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid.","volume":"19","author":"Angulo","year":"1999","journal-title":"Liver"},{"key":"R21-9-20241201","first-page":"106","article-title":"Primary biliary cirrhosis: diagnosis, pathology and pathogenesis.","volume":"4","author":"Scheuer","year":"1983","journal-title":"Postgrad Med J"},{"key":"R22-9-20241201","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0168-8278(00)80216-0","article-title":"Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial.","volume":"32","author":"Pares","year":"2000","journal-title":"J Hepatol"},{"key":"R23-9-20241201","doi-asserted-by":"crossref","first-page":"210A","DOI":"10.1016\/S0270-9139(03)80155-6","article-title":"The primary biliary cirrhosis (PBC) ursodiol (UDCA) plus methotrexate (MTX) or its placebo study (PUMPS)a multicenter randomized trial. abstract.","volume":"38","author":"Combes","year":"2003","journal-title":"HEPATOLOGY"},{"key":"R24-9-20241201","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1002\/hep.510290603","article-title":"Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. UDCA-PBC Study Group.","volume":"29","author":"Poupon","year":"1996","journal-title":"HEPATOLOGY"},{"key":"R25-9-20241201","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1056\/NEJM199807093390201","article-title":"A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.","volume":"339","author":"Lai","year":"1998","journal-title":"N Engl J Med"},{"key":"R26-9-20241201","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJM198202113060602","article-title":"A prospective trial of D-penicillamine in primary biliary cirrhosis.","volume":"306","author":"Matloff","year":"1982","journal-title":"N Engl J Med"},{"key":"R27-9-20241201","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/hep.510230108","article-title":"Time course of histological progression in primary biliary cirrhosis.","volume":"23","author":"Locke","year":"1996","journal-title":"HEPATOLOGY"},{"key":"R28-9-20241201","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1136\/gut.36.6.935","article-title":"Characterisation of patients with a complete biochemical response to ursodeoxycholic acid.","volume":"36","author":"Jorgensen","year":"1995","journal-title":"Gut"},{"key":"R29-9-20241201","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1136\/gut.46.1.121","article-title":"Characterization of patients with primary biliary cirrhosis responding to long term ursodeoxycholic acid therapy.","volume":"46","author":"Leuschner","year":"2000","journal-title":"Gut"},{"key":"R30-9-20241201","first-page":"392A","article-title":"Absence of pulmonary toxicity in primary biliary cirrhosis (PBC) treated with methotrexate and ursodiol. abstract.","volume":"28","author":"Munoz","year":"1998","journal-title":"HEPATOLOGY"},{"key":"R31-9-20241201","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1159\/000248822","article-title":"Methotrexate-induced liver cirrhosis: a follow-up.","volume":"175","author":"Zachariae","year":"1987","journal-title":"Dermatologica"},{"key":"R32-9-20241201","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1002\/hep.1840120427","article-title":"Methotrexate hepatotoxicity and the premature reporting of Mark Twains death: both greatly exaggerated.","volume":"12","author":"Kaplan","year":"1990","journal-title":"HEPATOLOGY"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.20103","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-200404000-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T12:02:20Z","timestamp":1733054540000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-200404000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,4]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2004]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.20103","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2004,4]]}}}